鶹ý

More ADHD Drug Production; Psilocybin vs Lexapro; Addiction a Chronic Brain Disease?

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

Amid ongoing shortages, the U.S. Drug Enforcement Administration is of Takeda Pharmaceuticals' attention deficit-hyperactivity disorder (ADHD) drug lisdexamfetamine (Vyvanse) and its generics. (Reuters)

Is a chain of psychiatric hospitals to maximize insurance payments? (New York Times)

High-dose psilocybin yielded than placebo and escitalopram (Lexapro) in a meta-analysis of antidepressant trials. (The BMJ)

More than one in five people who in 2022 had a non-substance-related mental health disorder, most commonly depression or anxiety. (Morbidity and Mortality Weekly Report)

Kids with had higher increases in BMI than peers without from 2004 to 2020, a Swedish cross-sectional study found. (JAMA Network Open)

Researchers in Schizophrenia argued for a for patients with early-stage schizophrenia that slightly diverges from established algorithms.

Suicide deaths were who did not undergo surgery. (JAMA Network Open)

Risk for for Korean adults taking an SGLT-2 inhibitor versus a DPP-4 inhibitor for type 2 diabetes, a population-based cohort study found. (The BMJ)

The New York Times examined efforts to rethink whether addiction should be considered .

While telemedicine was only used in 13.9% of all initiations, it still "may play an important role" in the process, said researchers in JAMA Network Open.

Baseline cognition didn't moderate the , a pooled analysis of four trials suggested. (Journal of Clinical Psychiatry)

After two fatal New Jersey police shootings of , a state policy will change how officers respond to mental health calls. (CBS News)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.